Cary, NC — APIE Therapeutics, a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), announced the appointment of Jim...
Read MoreNews
APIE Therapeutics Provides Evidence that Activating
Presentation at IPF Summit Elucidates APT-101 Mechanism of Action
Read MoreAPIE Therapeutics Presented Preclinical Findings Supporting
APIE Selected for Oral Presentation at the International Workshop of Scleroderma Research
Read MoreAPIE Therapeutics Augments Leadership Team with
APIE Therapeutics appoints Debra K. Bowes, MBEE and Seth Hetherington, M.D. to the positions of chief business officer and chief medical officer, respectively.
Read MoreAPIE Therapeutics Prepares to Advance Pipeline
APIE Therapeutics appoints Robert Willette, Ph.D. to the newly created role of chief scientific officer.
Read MoreAPIE Therapeutics Expands Board of Directors
Diane K. Jorkasky, M.D. FACP brings over three decades of experience in all stages of clinical development to the APIE Therapeutics board.
Read MoreRTI International Licenses Portfolio of Compounds
The agreement advances APIE Therapeutics’ pursuit of a treatment for idiopathic pulmonary fibrosis, a rare lung disease
Read MoreEvents
IPF Summit 2022
During the IPF Summit, APIE Therapeutics presented a poster describing the novel apelin receptor agonist…
International Workshop of Scleroderma Research
Preclinical results support the potential of APT-101 as a therapeutic for ILD, including those cases…
APIE Therapeutics chosen as Start-Up Stadium Finalist
Start-Up Stadium was designed to provide start-up companies with the opportunity to access key members…
RESI JPM 2022
The Redefining Early Stage Investments (RESI) conference series connects start-ups and early-stage investors with strategic…
